膀胱がん治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Bladder Cancer - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0629
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:1626
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥262,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD5,000 ⇒換算¥525,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD7,500 ⇒換算¥787,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Bladder Cancer – Pipeline Review, H2 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Bladder Cancer – Pipeline Review, H2 2019, provides an overview of the Bladder Cancer (Oncology) pipeline landscape.

Bladder cancer occurs in tissues of the urinary bladder. Symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body and burning during urination. Risk factors for bladder cancer include smoking, exposure to substances such as rubber, certain dyes and textiles, paint, and hairdressing supplies, diet rich in fried meats and fat, old age, sex and color, certain parasitic infections. Treatment of bladder cancer includes chemotherapy, surgery, biological therapy and radiation therapy.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Bladder Cancer – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Bladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 10, 73, 85, 1, 2, 81, 8 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 8, 4, 1, 13 and 3 molecules, respectively.

Bladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Bladder Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Bladder Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bladder Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bladder Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bladder Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bladder Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bladder Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Bladder Cancer – Overview
Bladder Cancer – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Bladder Cancer – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bladder Cancer – Companies Involved in Therapeutics Development
Bladder Cancer – Drug Profiles
4SC-205 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
9-ING41 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AB-154 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bladder Cancer – Dormant Projects
Bladder Cancer – Discontinued Products
Bladder Cancer – Product Development Milestones
Featured News & Press Releases
Dec 09, 2019: Sesen Bio initiates rolling submission of BLA for Vicinium to FDA
Dec 05, 2019: FerGene announces pivotal phase 3 study of nadofaragene firadenovec met its primary endpoint with more than half of patients with high-grade non-muscle invasive bladder cancer (CIS Ta/T1) achieving a complete response at three months
Dec 04, 2019: Sesen Bio completes successful CMC Type B pre-BLA Meeting with FDA
Dec 02, 2019: FDA grants priority review to Merck’s supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab) in certain patients with high-risk, non-muscle invasive bladder cancer (NMIBC)
Nov 27, 2019: Theralase researchers receive recognition for recent scientific publications
Nov 26, 2019: Cancer Research UK: Bladder cancer treatment rejected for routine use on NHS in England
Nov 08, 2019: Neon Therapeutics announces updated data presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Nov 06, 2019: 4D pharma: Preliminary safety and clinical observations from its Phase I/II study of MRx0518 in combination with KEYTRUDA
Nov 05, 2019: Sesen Bio Announces successful type C meeting with FDA for Vicinium
Oct 23, 2019: EpiVax Oncology announces three abstracts accepted for presentation at the 34th Annual Meeting of the Society for Immunotherapy of Cancer
Oct 21, 2019: Bavarian Nordic reports Phase II bladder cancer trial data
Oct 07, 2019: London Health Sciences Centre launches as newest clinical study site for phase II Non-Muscle Invasive Bladder Cancer clinical study
Oct 01, 2019: Roche’s Tecentriq performs well in untreated bladder cancer
Oct 01, 2019: Theralase files Investigational New Drug application with the FDA
Sep 30, 2019: Patient Six Cancer-Free Eighteen Months After Single Anti-Cancer Treatment
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Bladder Cancer, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Route of Administration, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Bladder Cancer - Pipeline by 4D Pharma Plc, H2 2019
Bladder Cancer - Pipeline by 4SC AG, H2 2019
Bladder Cancer - Pipeline by Aadi Bioscience Inc, H2 2019
Bladder Cancer - Pipeline by AbbVie Inc, H2 2019
Bladder Cancer - Pipeline by Abivax SA, H2 2019
Bladder Cancer - Pipeline by Actuate Therapeutics Inc, H2 2019
Bladder Cancer - Pipeline by ADC Therapeutics SA, H2 2019
Bladder Cancer - Pipeline by Advaxis Inc, H2 2019
Bladder Cancer - Pipeline by Agenus Inc, H2 2019
Bladder Cancer - Pipeline by AIM ImmunoTech Inc, H2 2019
Bladder Cancer - Pipeline by Alligator Bioscience AB, H2 2019
Bladder Cancer - Pipeline by Alphamab Oncology, H2 2019
Bladder Cancer - Pipeline by Altor Bioscience LLC, H2 2019
Bladder Cancer - Pipeline by Amrita Therapeutics, H2 2019
Bladder Cancer - Pipeline by Andes Biotechnologies, H2 2019
Bladder Cancer - Pipeline by Apexian Pharmaceuticals Inc, H2 2019
Bladder Cancer - Pipeline by APIM Therapeutics AS, H2 2019
Bladder Cancer - Dormant Projects, H2 2019
Bladder Cancer - Discontinued Products, H2 2019
Bladder Cancer - Discontinued Products, H2 2019 (Contd..1), H2 2019

【掲載企業】

4D Pharma Plc
4SC AG
Aadi Bioscience Inc
AbbVie Inc
Abivax SA
Actuate Therapeutics Inc
ADC Therapeutics SA
Advaxis Inc
Agenus Inc
AIM ImmunoTech Inc
Alligator Bioscience AB
Alphamab Oncology
Altor Bioscience LLC
Amrita Therapeutics
Andes Biotechnologies
Apexian Pharmaceuticals Inc
APIM Therapeutics AS
Apollomics Inc
Aravive Inc
Archivel Farma SL
Arcus Biosciences Inc
Arisaph Pharmaceuticals Inc
Asieris Pharmaceuticals Co Ltd
AstraZeneca Plc
Aura Biosciences Inc
Aurigene Discovery Technologies Ltd
Aurora Oncology Inc
Bavarian Nordic A/S
Bayer AG
BeiGene Ltd
Beijing Neoantigen Biotechnology Co Ltd
BerGenBio ASA
Betta Pharmaceuticals Co Ltd
BeyondSpring Inc
Bio-Thera Solutions Ltd
Biocad
Biohaven Pharmaceutical Holding Company Ltd
BioMed Valley Discoveries Inc
Biomics Biotechnologies Co Ltd
BioNTech SE
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Cantargia AB
Celgene Corp
CellCentric Ltd
Celldex Therapeutics Inc
Celon Pharma SA
Celprogen Inc
Celsion Corp
Celyad SA
CheckPoint Immunology Inc
CicloMed LLC
Cleveland BioLabs Inc
CMG Pharmaceutical Co Ltd
Cold Genesys Inc
Constellation Pharmaceuticals Inc
Convalife
Corvus Pharmaceuticals Inc
Cristal Therapeutics BV
CStone Pharmaceuticals Co Ltd
CytomX Therapeutics Inc
Daiichi Sankyo Co Ltd
DelMar Pharmaceuticals Inc
Ectin Research AB
Eddingpharm Inc
Eisai Co Ltd
Elsalys Biotech SA
enGene Inc
EnGeneIC Ltd
EpiThany Inc
EpiVax Oncology Inc
Esperance Pharmaceuticals Inc
Evelo Biosciences Inc
Exelixis Inc
Exicure Inc
F. Hoffmann-La Roche Ltd
F1 Oncology Inc
Fidia farmaceutici SpA
FKD Therapies Oy
For-Robin Inc
Forty Seven Inc
Gene Signal International SA
Genentech Inc
Genexine Inc
Genmab A/S
Genome & Co
Gilead Sciences Inc
GlaxoSmithKline Plc
GLG Pharma SA
H3 Biomedicine Inc
Hamlet Pharma AB
Hanmi Pharmaceuticals Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
HengRui YuanZheng Bio-Technology Co Ltd
Hope Biosciences Inc
Horizon Therapeutics PLC
I-Mab Biopharma Co Ltd
Immunocore Ltd
Immunomic Therapeutics Inc
ImmunSYS Inc
Immupharma Plc
Imugene Ltd
IMV Inc
Incanthera Ltd
Incyte Corp
Innovative Cellular Therapeutics Co Ltd
Innovent Biologics Inc
Iovance Biotherapeutics Inc
Johnson & Johnson
KLUS Pharma Inc
Komipharm International Co Ltd
Kyowa Kirin Co Ltd
Lipac Oncology LLC
LipoMedix Pharmaceutical Inc
LipoSeuticals Inc
Loxo Oncology Inc
Luye Pharma Group Ltd
Machavert Pharmaceuticals LLC
MacroGenics Inc
Manhattan Biosolutions LLC
MaxiVAX SA
Medivir AB
MedPacto Inc
MELEMA Pharma GmbH
Memgen LLC
Merck & Co Inc
Merck KGaA
Midissia Therapeutics Inc
Millennium Pharmaceuticals Inc
Modra Pharmaceuticals BV
Molecular Partners AG
Molecular Templates Inc
Moleculin Biotech LLC
Morvus Technology Ltd
MTG Biotherapeutics Inc
Mustang Bio Inc
NanoCarrier Co Ltd
Nanology LLC
NantKwest Inc
Nektar Therapeutics
Neon Therapeutics Inc
NeoTX Therapeutics Ltd
NGM Biopharmaceuticals Inc
Northwest Biotherapeutics Inc
Novartis AG
Ona Therapeutics SL
OncoTherapy Science Inc
Oncovir Inc
Ono Pharmaceutical Co Ltd
Optimum Therapeutics LLC
Oxford BioTherapeutics Ltd
Peptron Inc
Pfizer Inc
Pharma Mar SA
Pieris Pharmaceuticals Inc
Plus Therapeutics Inc
Provecs Medical GmbH
PsiOxus Therapeutics Ltd
Puma Biotechnology Inc
Qu Biologics Inc
Ractigen Therapeutics Inc
Rainier Therapeutics Inc
Recursion Pharmaceuticals Inc
RemeGen Ltd
Replimune Ltd
Rexahn Pharmaceuticals Inc
Sanofi
Sareum Holdings Plc
Savoy Pharmaceuticals Inc
Scholar Rock Inc
Seattle Genetics Inc
Serum Institute of India Ltd
Sesen Bio Inc
SetLance srl
Shandong Boan Biological Technology Co Ltd
Shionogi & Co Ltd
Sierra Oncology Inc
Sillajen Biotherapeutics
Sitka Biopharma Inc
Spectrum Pharmaceuticals Inc
Spring Bank Pharmaceuticals Inc
Stcube Inc
Syndax Pharmaceuticals Inc
Tara Immuno-Oncology Therapeutics LLC
Targovax ASA
Taris Biomedical LLC
Tessa Therapeutics Pte Ltd
Theralase Technologies Inc
Tmunity Therapeutics Inc
Tocagen Inc
Tolero Pharmaceuticals Inc
Toray Industries Inc
Transgene SA
Treos Bio Ltd
UbiVac LLC
UroGen Pharmaceuticals Ltd
VasGene Therapeutics Inc
Vault Pharma Inc
Vaxiion Therapeutics Inc
Viralytics Pty Ltd
Vivlmmune Inc
Vyriad Inc
Xbrane Biopharma AB
Xiangxue Life Sciences
Zhejiang Teruisi Pharmaceutical Inc
Zhejiang Yangshengtang Biotech Co Ltd
Zymeworks Inc


【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[膀胱がん治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆